| Literature DB >> 34125232 |
Martijn H van der Ree1, Jeroen Vendrik1, Tom E Verstraelen1, Jan A Kors2, Ahmad S Amin1, Arthur A M Wilde1, Hanno L Tan1,3, Pieter G Postema1.
Abstract
AIMS: In patients with Brugada syndrome (BrS) but without spontaneous Type-1 electrocardiogram, several electrocardiographic characteristics have been studied, including the β-angle. Previous studies suggested that the β-angle might be useful in distinguishing BrS-patients from patients with only suggestive repolarization patterns without performing sodium channel blocker provocation testing. In this study, we aimed to determine the diagnostic value of the β-angle in patients suspected of BrS. METHODS ANDEntities:
Keywords: Brugada syndrome; Diagnostic characteristics; Electrocardiographic characteristics; β-angle
Mesh:
Substances:
Year: 2021 PMID: 34125232 PMCID: PMC8651167 DOI: 10.1093/europace/euab128
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.214
Baseline characteristics
| Characteristic | Ajmaline test positive ( | Ajmaline test negative ( |
|
|---|---|---|---|
| Age (years) | 45 (35–55) | 42 (30–54) | 0.003 |
| Male | 175 (51) | 563 (54) | 0.325 |
| Length (cm) | 174 ± 11 | 177 ± 10 | <0.001 |
| Weight (kg) | 77 ± 15 | 78 ± 15 | 0.120 |
| BMI (kg/m2) | 25 ± 4 | 25 ± 4 | 0.513 |
| History of SVT | 6 (2) | 29 (3) | 0.329 |
| History of VT/VF | 12 (4) | 51 (5) | 0.370 |
| History of syncope | 63 (18) | 154 (15) | 0.124 |
| Family history of SCD/SUD | 170 (49) | 582 (56) | 0.040 |
| Family history of BrS | 171 (50) | 389 (37) | <0.001 |
| Genetic testing | 209 (61) | 95 (9) | <0.001 |
| (Likely) pathogenic SCN5A variant | 29 (14 | 8 (8 | 0.192 |
| Likely pathogenic | 14 (48 | 7 (88 | 0.104 |
| Pathogenic | 15 (52 | 1 (13 | 0.104 |
| Indication for test | |||
|
| 73 (21) | 130 (12) | <0.001 |
|
| 26 (8) | 79 (8) | 1.000 |
|
| 173 (50) | 393 (38) | <0.001 |
|
| 73 (21) | 444 (42) | <0.001 |
| Ajmaline administered (mg) | 73 ± 24 | 81 ± 16 | <0.001 |
| Percentage of target dose (%) | 95 ± 28 | 104 ± 10 | <0.001 |
Data are presented as mean ± SD, median (IQR), or n (%).
BMI, body mass index; BrS, Brugada syndrome; SCD, sudden cardiac death; SVT, supraventricular tachycardia; SUD, sudden unexplained death; VT, ventricular tachycardia; VF, ventricular fibrillation.
Patients who underwent genetic testing.
Total group.
Patients with a (likely) pathogenic mutation.
Electrocardiogram parameters at baseline
| Ajmaline test positive ( | Ajmaline test negative ( |
| |
|---|---|---|---|
| Heart rate (b.p.m.) | 67 ± 13 | 65 ± 12 | 0.003 |
| P-wave duration (ms) | 116 ± 14 | 114 ± 15 | 0.005 |
| PR-interval (ms) | 168 ± 29 | 160 ± 27 | <0.001 |
| QRS-duration (ms) | 104 ± 15 | 99 ± 13 | <0.001 |
| S-duration in | 55 (17) | 97 (10) | 0.001 |
| S-amplitude in | 144 (43) | 405 (41) | 0.441 |
| JT-duration (ms) | 301 ± 28 | 312 ± 31 | <0.001 |
| Max. J-amplitude in V1-V2ic3 (µV) | 106 ± 87 | 85 ± 65 | <0.001 |
| QT-interval (ms) | 405 ± 29 | 411 ± 31 | 0.001 |
| QTc-interval (ms) | 424 ± 27 | 423 ± 27 | 0.627 |
| P-axis (°) | 55 (37–67) | 52 (35–64) | 0.050 |
| QRS-axis (°) | 31 ± 41 | 40 ± 38 | <0.001 |
| T-axis (°) | 40 ± 20 | 38 ± 23 | 0.193 |
Data are presented as mean ± SD, median (IQR), or n (%).
β-angle and duration at base of 5 mm triangle compared between patients with a positive test and with a negative test.
| Measurable number of patients and % of cohort | Ajmaline test positive ( | Ajmaline test negative ( |
| |
|---|---|---|---|---|
| β-angle | ||||
| β-angle in V1 (°) | 52 (4%) | 28 (20–47) ( | 18 (12–24) ( | 0.004 |
| β-angle in V2 (°) | 35 (3%) | 33 (15–64) ( | 19 (13–25) ( | 0.103 |
| β-angle in V1ic3 (°) | 133 (10%) | 36 (27–58) ( | 23 (17–30) ( | <0.001 |
| β-angle in V2ic3 (°) | 134 (10%) | 31 (21–46) ( | 21 (14–28) ( | <0.001 |
| β-angle in V1ic2 (°) | 517 (37%) | 29 (21–37) ( | 22 (15–28) ( | <0.001 |
| β-angle in V2ic2 (°) | 469 (34%) | 25 (18–33) ( | 18 (14–25) ( | <0.001 |
| DBT | ||||
| DBT in V1 (ms) | 51 (4%) | 130 (89–214) ( | 65 (42–92) ( | 0.002 |
| DBT in V2 (ms) | 32 (2%) | 187 (56–463) ( | 69 (43–89) ( | 0.048 |
| DBT in V1ic3 (ms) | 127 (9%) | 148 (106–317) ( | 85 (61–115) ( | <0.001 |
| DBT in V2ic3 (ms) | 107 (8%) | 120 (77–214) ( | 77 (47–110) ( | <0.001 |
| DBT in V1ic2 (ms) | 506 (36%) | 109 (77–151) ( | 77 (54–102) ( | <0.001 |
| DBT in V2ic2 (ms) | 461 (33%) | 93 (65–128) ( | 65 (50–93) ( | <0.001 |
Data are presented as median (IQR).
DBT, duration at the base of the triangle.
Diagnostic characteristics of the previously reported β-angle cut-off values for the largest angle in V1 and/or V2.
| Cut-off | 23° | 36.8° | 38.6° | 58° | |||||
|---|---|---|---|---|---|---|---|---|---|
| Publication | van der Ree | Ohkubo | van der Ree | Serra | van der Ree | Serra | van der Ree | Chevallier | Gottschalk |
| PPV (%) | 45 | 76 | 88 | 94 | 100 | 94 | 100 | 73 | 75 |
| NPV (%) | 87 | 100 | 80 | 89 | 81 | 88 | 75 | 87 | 64 |
| Sensitivity (%) | 77 | 100 | 41 | 86 | 41 | 85 | 17 | 79 | 60 |
| Specificity (%) | 62 | 54 | 98 | 95 | 100 | 96 | 100 | 83 | 78 |
| Youden index | 0.38 | 0.54 | 0.39 | 0.81 | 0.41 | 0.81 | 0.18 | 0.62 | 0.38 |
NPV, negative predictive value; PPV, positive predictive value.
Youden index: (sensitivity + specificity) − 1.